Tibet Weixinkang Medicine Co Ltd (603676) — Cash Flow-to-Debt Ratio
Tibet Weixinkang Medicine Co Ltd (603676) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of CN¥13.68 Million could theoretically repay 0% of its total liabilities (CN¥382.95 Million) in one year. Check Tibet Weixinkang Medicine Co Ltd (603676) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tibet Weixinkang Medicine Co Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Tibet Weixinkang Medicine Co Ltd across 13 annual periods. Also explore 603676 total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Tibet Weixinkang Medicine Co Ltd (2013–2025)
Year-by-year debt coverage analysis for Tibet Weixinkang Medicine Co Ltd. For market capitalisation and broader financial context, see 603676 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.48x | CN¥185.53 Million | CN¥390.49 Million | ▼ -40.3% |
| 2024 | 0.80x | CN¥372.78 Million | CN¥468.24 Million | ▲ +35.4% |
| 2023 | 0.59x | CN¥256.67 Million | CN¥436.55 Million | ▲ +6.1% |
| 2022 | 0.55x | CN¥246.15 Million | CN¥444.13 Million | ▲ +39.1% |
| 2021 | 0.40x | CN¥170.69 Million | CN¥428.31 Million | ▲ +12.3% |
| 2020 | 0.35x | CN¥133.70 Million | CN¥376.85 Million | ▲ +25.0% |
| 2019 | 0.28x | CN¥106.34 Million | CN¥374.56 Million | ▲ +15.2% |
| 2018 | 0.25x | CN¥83.17 Million | CN¥337.33 Million | ▼ -38.2% |
| 2017 | 0.40x | CN¥63.30 Million | CN¥158.58 Million | ▼ -64.3% |
| 2016 | 1.12x | CN¥103.79 Million | CN¥92.94 Million | ▲ +3.2% |
| 2015 | 1.08x | CN¥114.47 Million | CN¥105.82 Million | ▼ -29.6% |
| 2014 | 1.54x | CN¥118.47 Million | CN¥77.09 Million | ▲ +6.7% |
| 2013 | 1.44x | CN¥88.59 Million | CN¥61.52 Million | — |